C4 Therapeutics, Inc. (CCCC)
CCCCNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$3.15
+0.0500 (+1.61%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $413.65m
- P/E
- –
- EPS, last 4 quarters
- $-0.7200
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.69 to $5.17
- Average volume
- 2.45m
- Previous close
- $3.10
Analysts
6 coveringBuy6 buy, 0 hold, 0 sell
Targets a year out average $8.80, +179.4% from here
Earnings
next estimate $-0.2400Next report
Dec 2025
+58.1%
Mar 2026
+4.8%
Jun 2026
+21.7%
Sep 2026
+20.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $11.23m | $11.02m | $6.15m | $6.64m |
| Gross profit | $11.23m | $11.02m | $6.15m | $6.64m |
| Operating income | -$34.41m | -$23.14m | -$27.79m | -$26.42m |
| Net income | -$32.17m | -$20.49m | -$25.13m | -$23.64m |
Last four quarters: revenue $35.04m, margin -289.4%, free cash flow -$85.39m
News
8 latest- C4 Therapeutics Reports Third Quarter 2026 Financial ResultsFintel · 4 days ago
- C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue EstimatesZacks · 5 days ago
- Acadia Pharmaceuticals (ACAD) Tops Q3 Earnings and Revenue EstimatesZacks · 5 days ago
- Lake Street Initiates Coverage of C4 Therapeutics with BuyFintel · Oct 29, 2026
- C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks · Oct 29, 2026
- Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?Zacks · Oct 9, 2026
- Cemsidomide Shows Immune Activation In C4 Therapeutics' Myeloma Study RTTNews · Sep 25, 2026
- Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?Zacks · Sep 23, 2026
The company
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T's degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- c4therapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.